Search clinical trials for: Gleevec (imatinib)

Total 1812 results

Boston Children's Hospital

Completed

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis (PVS)

Pulmonary Veno Occlusive Disease

United States
Emory University
Novartis

Terminated

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

Gastric Adenocarcinoma

United States
Baylor College of Medicine

Recruiting

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission | Chronic Myeloid Leukemia in Remission

United States
Dermatologic Cooperative Oncology Group

Completed

Imatinib in Dermatofibrosarcoma Protuberans (DFSP)

Dermatofibrosarcoma

Germany
Centre Leon Berard

Recruiting

Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)

C-KIT Mutation | Metastatic Gastrointestinal Stromal Tumor (GIST) | Advanced Gastrointestinal Stromal Tumor (GIST)

France
Poitiers University Hospital

Completed

Glivec in Pediatric Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia

France
New Mexico Cancer Care Alliance
Novartis; Fred Hutchinson Cancer Center

Completed

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer (6137p)

Non-small Cell Lung Cancer

United States
Fujian Medical University Union Hospital

Not yet recruiting

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST (PIRKER)

Gastrointestinal Stromal Tumor of Rectum

China
National Cancer Institute (NCI)

Terminated

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
American University of Beirut Medical Center

Recruiting

Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Lebanon
Novartis Pharmaceuticals

Completed

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

All Indications for Glivec/Gleevec and Tasigna

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
Prof. Dr. Nikolas von Bubnoff
Novartis

Terminated

An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years (DECLINE)

Chronic Myeloid Leukemia

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
M.D. Anderson Cancer Center

Terminated

Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma

Uterine Cancer

United States
Duke University
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Glioblastoma | Gliosarcoma

United States
Pusan National University Hospital

Available

The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder

Chronic Myeloid Leukemia
Novartis Pharmaceuticals

Completed

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Urogenital Neoplasms | Genital Neoplasms, Male | Prostatic Diseases | Antineoplastic Agents | Imatinib | Prostatic Neoplasm | Genital Diseases, Male | Neoplasms, Abdominal

Germany
Joanne Jeter
National Cancer Institute (NCI); Merck Ltd.

Withdrawn

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma
Norwegian University of Science and Technology

Completed

Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NordCML006)

Chronic Myeloid Leukemia

Sweden, Finland, Norway
Duke University

Terminated

Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571

Non-small Cell Lung Cancer
Duke University
National Cancer Institute (NCI)

Completed

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Brain and Central Nervous System Tumors

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa

Loiasis

Cameroon
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Kidney Cancer

United States
Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Leukemia, Chronic Myeloid

Italy
Il-Yang Pharm. Co., Ltd.

Active, not recruiting

Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Chronic Myeloid Leukemia, Chronic Phase

China
University of Michigan Rogel Cancer Center
Novartis

Withdrawn

RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

Chronic Myeloid Leukemia

United States
New Mexico Cancer Care Alliance

Completed

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

Cancer | Leukemia, Other

United States
First Affiliated Hospital, Sun Yat-Sen University

Completed

The Long-term Efficacy of Imatinib With Hepatic Resection or Other Local Treatment for GIST Liver Metastases

Liver Metastases | GIST, Malignant

China
Northwestern University
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Pancreatic Cancer

Pancreatic Cancer

United States
AEterna Zentaris
M.D. Anderson Cancer Center

Completed

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

Gastrointestinal Stromal Tumors
University of Utah
Schering-Plough

Terminated

Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients

Gastrointestinal Stromal Tumors | Solid Tumors | Cancer Brain

United States
Masaryk University

Active, not recruiting

Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia (HALF)

Chronic Myeloid Leukemia, Chronic Phase | Withdrawal;Drug

Czechia
Inova Health Care Services
Novartis Pharmaceuticals

Completed

New Individualized Therapy Trial for Metastatic Colorectal Cancer (NITMEC)

Colorectal Cancer | Colorectal Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia

Chronic Myeloid Leukemia, BCR-ABL1 Positive

United States, Canada
National Cancer Institute (NCI)

Terminated

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie

Terminated

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

ALK+ Anaplastic Large Cell Lymphoma

Austria
Henry M. Jackson Foundation for the Advancement...
Novartis

Completed

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer

United States
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-Small-Cell Lung

China
Central European Cooperative Oncology Group

Completed

Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Croatia, Bosnia and Herzegovina, Romania, Slovakia, Bulgaria, Czech Republic, Austria, Lithuania, Serbia, Slovenia
University of Nebraska
National Cancer Institute (NCI)

Completed

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

Leukemia

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

Canada, Italy, United States, United Kingdom, Belgium, Germany, France, Switzerland, Austria, Denmark, Spain, Norway, Sweden, Netherlands, New Zealand, Australia
Xiangya Hospital of Central South University
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Gastrointestinal Stromal Tumors

China
Novartis Pharmaceuticals

No longer available

Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination (MACS2226)

Gastrointestinal Stromal Tumor

China
Daewoong Pharmaceutical Co. LTD.

Completed

Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers

Healthy
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Leukemia

United States
Dong-A ST Co., Ltd.

Completed

A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)

Chronic Myeloid Leukemia | Gastrointestinal Stromal Tumor

Korea, Republic of

Search clinical trials for: Gleevec (imatinib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations